Combination Products Require Unique Risk-Benefit Analysis, Says Industry Expert

Companies manufacturing drug-device combination products must determine whether the benefits associated with each constituent part and the overall product outweigh the risks, says Susan Neadle, president of Combination Products Consulting…

Continue ReadingCombination Products Require Unique Risk-Benefit Analysis, Says Industry Expert

FDA Shares Quality Considerations for Ophthalmic Drugs in Draft Guidance

The FDA’s newest draft guidance discusses quality considerations for ophthalmic drugs, including ways to assess impurities, evaluate visible contaminants, design containers and conduct stability studies. Source: Drug Industry Daily

Continue ReadingFDA Shares Quality Considerations for Ophthalmic Drugs in Draft Guidance

Improved Industry Agility in Quality Management Contingent on Global Regulatory Framework, Says CDER Official

Establishing greater industry agility in quality management requires increased technical harmonization and regulatory convergence among global health agencies, says Theresa Mullin, associate director for strategic initiatives with CDER. Source: Drug…

Continue ReadingImproved Industry Agility in Quality Management Contingent on Global Regulatory Framework, Says CDER Official